Get started
666

CALIWAY BIOPHARMACEUTICALS CO LTD

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

6919 fundamentals

CALIWAY BIOPHARMACEUTICALS CO LTD financial statements, including revenue, expenses, profit, and loss

The total revenue of 6919 for the last quarter is 23.26β€―M TWD, and it's 196.34% higher compared to the previous quarter. The net income of Q3 24 is -137.57β€―M TWD.

Q1 '24
Q2 '24
Q3 '24
β€ͺ0.00‬
Total revenue
Gross profit
Operating income
Pretax income
Net income
Income statementBalance sheetCash flow
Currency: TWD
Q1 '24
Q2 '24
Q3 '24
TTM
Total revenueYoY growth
β€”
β€”
β€”
β€”
Cost of goods sold
β€”
β€”
β€”
β€”
Gross profitYoY growth
β€”
β€”
β€”
β€”
Operating expenses (excl. COGS)
β€”
β€”
β€”
β€”
Operating incomeYoY growth
β€”
β€”
β€”
β€”
Non-operating income, total
β€”
β€”
β€”
β€”
Pretax incomeYoY growth
β€”
β€”
β€”
β€”
Equity in earnings
β€”
β€”
β€”
β€”
Taxes
β€”
β€”
β€”
β€”
Non-controlling/minority interest
β€”
β€”
β€”
β€”
After tax other income/expense
β€”
β€”
β€”
β€”
Net income before discontinued operations
β€”
β€”
β€”
β€”
Discontinued operations
β€”
β€”
β€”
β€”
Net incomeYoY growth
β€”
β€”
β€”
β€”
Dilution adjustment
β€”
β€”
β€”
β€”
Preferred dividends
β€”
β€”
β€”
β€”
Diluted net income available to common stockholders
β€”
β€”
β€”
β€”
Basic earnings per share (Basic EPS)YoY growth
β€”
β€”
β€”
β€”
Diluted earnings per share (Diluted EPS)YoY growth
β€”
β€”
β€”
β€”
Average basic shares outstanding
β€”
β€”
β€”
β€”
Diluted shares outstanding
β€”
β€”
β€”
β€”
EBITDAYoY growth
β€”
β€”
β€”
β€”
EBITYoY growth
β€”
β€”
β€”
β€”
Total operating expenses
β€”
β€”
β€”
β€”